CLINICAL STUDY
General Pain – 84.1% reduction; P=0.006
Range of Motion Associated Pain – 74.7% reduction; P=0.020
Flexibility – 45.5% increase; P=0.005
The study results showed that TendoGuard™ when taken at a dosage of 375mg – 500mg twice per day appears to benefit joint inflammation, secondary mobility and other tertiary effects. The study shows that TendoGuard™ may be a viable treatment option for the management of joint and connective tissue disorders.